Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals announced the dosing of the first U.S. patient in COVE-3, the second pivotal Phase 3 trial evaluating YCANTH for common warts, while partner Torii Pharmaceutical dosed the first patient in Japan. Torii will fund the first $40 million of trial costs—approximately 90% of the current budget—before splitting costs 50/50, with Verrica's share paid from future Japanese royalties.
Key figures
- Drug Name
- YCANTH (VP-102)
- Phase Of Trial
- Phase 3
- Trial funding amount
- $40 million
- Trial budget coverage
- 90%
- Cohort 2 clearance rate
- 51%
- Common warts prevalence us
- 22 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.